Chimerix Acquires Oncoceutics to Expand Pipeline with Late-Stage Oncology Program
Chimerix Acquires Oncoceutics to Expand Pipeline with Late-Stage Oncology Program January 08, 2021 06:00 ET | Source: Chimerix, Inc. Chimerix, Inc. ONC201 Registrational Trial for Recurrent H3 K27M-mutant Glioma Compelling Response Rates to Date; Defined Regulatory Path to Registration Pivotal Data Anticipated in 2021 to Support Potential Registration, Addressing an Estimated Market Opportunity of Greater than $500 Million Management to Host Conference Call at 8:30 a.m. ET Today DURHAM, N.C., Jan. 08, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceu...
Source: globenewswire.com